Comparative analysis of the efficacy and safety of modified FOLFOX-6 and DCF regimens as first-line treatment in advanced gastric cancer

Basit Öğe Kaydı
dc.authoridCicin, Irfan/0000-0002-7584-3868
dc.authoridHacıbekiroğlu, İlhan/0000-0002-0333-7405
dc.authorwosidErdogan, Bulent/AAA-9781-2021
dc.authorwosidCicin, Irfan/AAQ-5575-2020
dc.authorwosidHacıbekiroğlu, İlhan/JCN-7264-2023
dc.contributor.authorHacibekiroglu, Ilhan
dc.contributor.authorKodaz, Hilmi
dc.contributor.authorErdogan, Bulent
dc.contributor.authorTurkmen, Esma
dc.contributor.authorEsenkaya, Asim
dc.contributor.authorOnal, Yilmaz
dc.contributor.authorUzunoglu, Sernaz
dc.date.accessioned2024-06-12T10:59:43Z
dc.date.available2024-06-12T10:59:43Z
dc.date.issued2015
dc.departmentTrakya Üniversitesien_US
dc.description.abstractThe aim of this study was to retrospectively compare the efficacy and toxicity of the oxaliplatin + 5-fluorouracil (5-FU) + leucovorin (LV) regimen [modified (m) FOLFOX-6] with that of the docetaxel + cisplatin + 5-FU regimen (DCF) in patients with advanced gastric cancer (AGC). A total of 72 patients received DCF (75 mg/m(2) docetaxel and 75 mg/m(2) cisplatin on day 1 and 750 mg/m(2) 5-FU on days 1-5) every 21 days, whereas 54 patients received mFOLFOX-6 (85 mg/m(2) oxaliplatin and 400 mg/m(2) LV as a 2-h infusion, followed by a 5-FU bolus of 400 mg/m(2) and 2,400 mg/m(2) 5-FU as a 46-h continuous infusion) every 14 days. In the DCF arm, 55 (76.4%) of the patients received prophylactic granulocyte colony-stimulating factor (G-CSF), 48-72 h following completion of chemotherapy. The median follow-up of the study was 12.1 months. The overall response rate (ORR) was 37.0% for mFOLFOX-6 and 40.3% for DCF (P=0.72). The median time to progression was 6.5 and 6.2 months in the mFOLFOX-6 and DCF arms, respectively (P=0.70). The median overall survival was 11.4 and 13.5 months in the mFOLFOX-6 and DCF arms, respectively (P=0.72). The rates of hematological toxicity did not differ between the two arms. However, in the subgroup analysis, grade 3-4 neutropenia and febrile neutropenia were significantly more common among patients who had not received G-CSF prophylaxis in the DCF arm. The incidence of grade 3-4 nausea/vomiting and diarrhea were significantly higher in the DCF arm. In conclusion, the present study demon-strated that the efficacy of the mFOLFOX-6 regimen was comparable to that of the DCF regimen in AGC patients. In addition, the benefit of G-CSF prophylaxis in conjunction with the DCF regimen was demonstrated.en_US
dc.identifier.doi10.3892/mco.2015.592
dc.identifier.endpage1164en_US
dc.identifier.issn2049-9450
dc.identifier.issn2049-9469
dc.identifier.issue5en_US
dc.identifier.pmid26623070en_US
dc.identifier.startpage1160en_US
dc.identifier.urihttps://doi.org/10.3892/mco.2015.592
dc.identifier.urihttps://hdl.handle.net/20.500.14551/20552
dc.identifier.volume3en_US
dc.identifier.wosWOS:000453157500035en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpandidos Publ Ltden_US
dc.relation.ispartofMolecular And Clinical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDocetaxel + Cisplatin + 5-Fluorouracil Regimenen_US
dc.subjectOxaliplatin + 5-Fluorouracil + Leucovorin Regimenen_US
dc.subjectGastric Canceren_US
dc.subjectFirst-Lineen_US
dc.subjectColony-Stimulating Factoren_US
dc.subjectPhase-Ii Trialen_US
dc.subjectFolinic Aciden_US
dc.subjectInfusional Fluorouracilen_US
dc.subjectFebrile Neutropeniaen_US
dc.subjectWeekly Oxaliplatinen_US
dc.subjectSupportive Careen_US
dc.subjectPlus Cisplatinen_US
dc.subjectBreast-Canceren_US
dc.subjectChemotherapyen_US
dc.titleComparative analysis of the efficacy and safety of modified FOLFOX-6 and DCF regimens as first-line treatment in advanced gastric canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu